<--- Back to Details
First PageDocument Content
Medicine / Health / Hepatitis / Boceprevir / Cytokines / Ribavirin / Hepatitis C / Interferon / Clinical trial / Protease inhibitors / Antivirals / Pharmacology
Date: 2012-11-14 10:56:38
Medicine
Health
Hepatitis
Boceprevir
Cytokines
Ribavirin
Hepatitis C
Interferon
Clinical trial
Protease inhibitors
Antivirals
Pharmacology

Best Practice/ Tool/Guideline

Add to Reading List

Source URL: globalhepc.files.wordpress.com

Download Document from Source Website

File Size: 147,97 KB

Share Document on Facebook

Similar Documents

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

IMPORTANT PLEASE READ PART III: CONSUMER INFORMATION INTRON A® interferon alfa-2b This leaflet is part III of a three-part "Product Monograph"

DocID: 1uNBi - View Document

Evaluation of Interferon-gamma-Producing T Cells

DocID: 1uFKZ - View Document

PRODUCT MONOGRAPH INTRON A® interferon alfa-2b Lyophilized Powder with Diluent: 10 million IU interferon alfa-2b/vial

DocID: 1umTG - View Document

  Data Sheet Recombinant Human Interferon-gamma (rh IFN-) Preclinical Grade - Order No.: µg)

DocID: 1u1rK - View Document